RIT-I-000/RIT-I-000A: Phase I Study of Radiolabeled Monoclonal Antibody Anti B1 for the Treatment of B Cell Lymphomas & RIT-I-000B: Extended Phase I/II Study to Determine the Safety and Efficacy of Coulter Clone 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma.

Trial Profile

RIT-I-000/RIT-I-000A: Phase I Study of Radiolabeled Monoclonal Antibody Anti B1 for the Treatment of B Cell Lymphomas & RIT-I-000B: Extended Phase I/II Study to Determine the Safety and Efficacy of Coulter Clone 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Iodine-131 tositumomab (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Feb 2012 Actual end date (October 2009) added as reported by ClinicalTrials.gov.
    • 16 Feb 2012 Company added (GlaxoSmithKline) in association, actual initiation date (April 1990), Official Title amended, lead trial centre identified as reported by ClinicalTrials.gov.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top